27 Jun, EOD - Indian

Nifty Pharma 21928.6 (0.55)

Nifty Smallcap 100 18976.8 (0.91)

Nifty IT 38822.95 (-0.44)

Nifty Next 50 68712.4 (0.61)

SENSEX 84058.9 (0.36)

Nifty Bank 57443.9 (0.41)

Nifty 50 25637.8 (0.35)

Nifty Midcap 100 59385.15 (0.27)

27 Jun, EOD - Global

NIKKEI 225 40150.79 (1.43)

HANG SENG 24284.15 (-0.17)

S&P 6232.75 (0.41)

LOGIN HERE

companylogoShree Ganesh Remedies Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 540737 | NSE Symbol : | ISIN : INE414Y01015 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |


Chairman's Speech

Dear Stakeholders,

I'm delighted to present Shree Ganesh Remedies Limited's Annual Report for the ?scal year 2023-24, titled ‘Expanding Horizons.' This year's theme re?ects the signi?cant strides we've made in solidifying our position as a leading building block chemical manufacturer and as a CDMO.

Performance:

We are proud to report a remarkable achievement – a revenue increase of over 37% from ?913.57 million in FY 2022-23 to ?1.25 billion this year. This robust performance is a testament to our unwavering commitment to continuous improvement and the collective effort of our dedicated team.

Prospects:

This year, we didn't just focus on performance; we invested strategically to expand our capabilities - to expand horizons. We signi?cantly expanded our research and production capabilities, allowing us to develop and offer a wider range of innovative products. Additionally, we've completed and commissioned our all new manufacturing block in the recently acquired plant, opening doors for exciting collaborations with stakeholders and contract partners.

913.57 MM to 1.25 Bn

37.80%

Revenue Expansion

Plan:

Looking ahead, we are fueled by a well-de?ned plan to leverage these advancements. We aim to utilize our enhanced research capabilities to develop differentiable solutions and explore new market opportunities. Our expanded production capacity will allow us to meet the growing demand for our products further strengthening our partnerships within the industry.

" Our team is full of energy as we look ahead of 2024. I am convinced that now is the time for us to set the course for future success.

In conclusion, FY 2023-24 has been a year of remarkable growth at Shree Ganesh Remedies. With a focus on ‘Expanding Horizons', we have laid the foundation for an even brighter future. We are con?dent that our commitment to innovation, collaboration, and operational excellence will propel us to even greater heights in the years to come.

Thank you for your continued support.

Jay Hind, Jay Bharat!

Sincerely,

Chandu Kothia Chairman, Shree Ganesh Remedies Limited

   

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +